Dostarlimab/Chemo Receives FDA Priority Review for Expanded

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

Related Keywords

, Prescription Drug User Fee Act , Endometrial Cancer , Dostarlimab , Fda , Priority Review ,